ClinicalTrials.Veeva

Menu
T

The Skin Hospital | Darlinghurst Clinic & Day Surgery - Research & Clinical Trials Unit

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Rocatinlimab
PF-06700841
PF-06651600
Ritlecitinib
Dupilumab
LY3009104
Baricitinib
Deucravacitinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 9 total trials
Locations recently updated

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Placebo
Drug: Baricitinib

The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab

The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in pediatric participants aged 4 to \<18 y...

Enrolling
Plaque Psoriasis
Other: Placebo matching deucravacitinib
Drug: Deucravacitinib

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Trial sponsors

AbbVie logo
Lilly logo
Pfizer logo
Amgen logo
Bristol-Myers Squibb (BMS) logo
P

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems